Company: BSX
Filing Date: 2025-08-01
Form Type: 10-Q
Source: 0000885725-25-000041
Chunk: 2

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-08-01
Form: 10-Q
Item: Part I, Item 2
Chunk 2
---
)161 19142—1420.10 Investment portfolio net losses (gains) and impairments(2)0(2)—(2)(0.00)European Union (EU) Medical device regulation (MDR) implementation costs10 19—90.01 Deferred tax expenses (benefits)— (45)45—450.03 Discrete tax items— (0)0—00.00 Adjusted$1,289 $162 $1,127 $0 $1,127 $0.75 

 Three Months Ended June 30, 2024(in millions, except per share data)Income (Loss) Before Income TaxesIncome Tax Expense (Benefit)Net Income (Loss)Net Income (Loss) Attributable to Noncontrolling InterestsNet Income (Loss) Attributable to Boston Scientific Common StockholdersImpact per ShareReported$420 $98 $322 $(2)$324 $0.22 Non-GAAP adjustments:Amortization expense213 29 184 2 182 0.12 Goodwill and other intangible asset impairment charges276 33 243 — 243 0.16 Acquisition/divestiture-related net charges (credits)49 11 38 — 38 0.03 Restructuring and restructuring-related net charges (credits)50 7 44 — 44 0.03 Investment portfolio net losses (gains) and impairments31 3 29 — 29 0.02 EU MDR implementation costs12 2 10 — 10 0.01 Deferred tax expenses (benefits)— (44)44 — 44 0.03 Adjusted$1,051 $138 $913 $(0)$914 $0.62 

40

Six Months Ended June 30, 2025

Our net sales for the first six months of 2025 were $9.724 billion, compared to $7.977 billion for the first six months of 2024. This increase of $1.747 billion, or 21.9 percent, included operational1 net sales growth of 21.9 percent and the neutral impact of less than one basis point from foreign currency fluctuations. Operational net sales growth included organic2 net sales growth of 17.8 percent and the positive impact of 410 basis points from